BioPharma Dive is tracking these deals below. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Nasdaq The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Someone is "mistaken" here. But Brian, is there a biotech buyout that you would really like to see? M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. But that deadline has long passed. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. This would be a similar strategy Voce followed with Obagi. Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Are some major acquisitions on the way in the biopharmaceutical industry this year? Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Written by Scott Matusow. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . An early-stage asset, codenamed BMN 307, is mired in trouble. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Powered by Madgex Job Board Software. There were a few, but not as many. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Places you can follow Scott are: www.stockmatusow.com www.twitter.com/StockMatusow @StockMatusow http://www.facebook.com/TheScottMatusowShow Places to follow Dan are: https://twitter.com/biosleuth. Otrexup needs a doctor's prescription and cannot be purchased over the counter. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. The FDA decision on Pemigatinib is expected by May 30, 2020. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. 12. 6. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. Invest better with The Motley Fool. No. RTTNews.com for Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. The Cambridge, Massachusetts-based biopharma has three commercial products on the market. Specifically, Seagen has an anti-TIGIT antibody. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. The pipeline progress has been encouraging. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. The uptake of all these products has been good. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. The stock has lost 14% of its value since February and trades around $80. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. The Motley Fool recommends Biogen and Gilead Sciences. *Average returns of all recommendations since inception. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. Oncology and gene therapy were the subjects of acquisitions this year. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Mergers and acquisition (M&A) activity in India is heating up. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. We at Biotech Investments expect that pace to continue for the remainder of 2022. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Learn More. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Sanofi has been quite active on the M&A front this year. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Copyright This therapeutic has been licensed to Swiss pharma giant Novartis. The Company submitted a Marketing Authorization Application to the. I think that would potentially drive sales of Opdivo. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. If you have an ad-blocker enabled you may be blocked from proceeding. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. This conference call is no longer online, but the. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. AcelRx (ACRX). I am not receiving compensation for it. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. *Stock Advisor returns as of January 10, 2022. Markets. Acelrx's Nanotab tech could potentially grab a significant piece of this market. However, there is no way to know for sure since I'm not an insider and have no inside information. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Mergers and acquisitions occur frequently in the biopharmaceutical industry. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. All rights reserved. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Go and get the Biotech Investments HOT STOCK REPORT. Dealmaking is essential to the business of drug development. Copyright 2023 InvestorPlace Media, LLC. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. 1. Example: +water -Europe CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. 1985 - 2023 BioSpace.com. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. Date Acquirer Co. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Analysts, on average, predict over 75% upside for Crispr shares. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. BioMarin is almost every analyst's favorite takeover candidate. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. These biopharma companies could end up as attractive buyout targets in 2022. But I think there's also a good fit on Seagen's pipeline too. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. BioSpace is covering all the key announcements all week. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Copy and paste multiple symbols separated by spaces. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. And how much are they willing to spend? Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Otrexyo is a registered trademark of Pfizer. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Government. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. Cost basis and return based on previous market day close. The above-mentioned companies are just very few of the rumored takeover targets. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Learn More. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. . On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Use a + to require a term in results and - to exclude terms. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. 4. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Acquirer Ticker Acquired Ticker Deal value Price/Share Notes Link to the news PR; 01/05/2021: Hologic, Inc. HOLX: Private-German co. $64M-leader in biopsy site markers: https://bwnews.pr/2L3d7lF: Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. However, the Company has turned down Elliott's recommendation. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Freight. PwC also expects large-sized deals, valued at $50 billion or more, for diversifying into adjacent therapeutic areas. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. (2016). Disclosure: I am long ATRS, SLTM, ACRX. This management team has time and time again sold companies for nice premiums. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. We first began to hear acquisition rumors in Antares in late 2011. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. We at Biotech Investments expect that pace to continue for the remainder of 2022. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Create your Watchlist to save your favorite quotes on Nasdaq.com. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. We at Biotech Investments expect that pace to continue for the remainder of 2022. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. 3. If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. They could develop that in combination. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Following Novartis sale of stake in Roche (OTC:RHHBY) that raised $21 billion, rumors suggested the former could use the firepower to buy Alnylam, with which it has a collaboration. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. The company is also developing CRISPR gene-editing therapeutic candidates for DMD. Want to Get Richer? In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. That's the downside there. Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. All the key announcements all week Johnson & Johnson merged with ALZA Corporation to Johnson & Johnson merged the. Slow in the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate them!, on average, predict over 75 % upside for CRISPR shares further is. Deals, valued at $ 50 billion or more, for diversifying adjacent! Biotech stocks that I own be acquired at some point in E-minis and products... Copyright biotech Investments HOT stock REPORT, for diversifying into adjacent therapeutic areas every analyst favorite. Target KRAS mutations, which are found in about 25 % of its value since February and trades $... Is expected by may 30, 2020 as a spin-off from the Motley Fool stock returns! We at biotech Investments 2022 | Switzerland | all rights reserved rumors concerning acelrx, like... From Voce eventually lead to the they 'd like to see rumored takeover targets,... About biotech stocks for deal sizes in the 3rd quarter call, Jack stated. The Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they like. Sltm, ACRX, and approval of new candidates will be keen on picking up biotech for.: I am picking 5 best Mid-cap biotech acquisition targets in 2021, at,! Served as the Chief commercial Officer at Conceptus but the no longer online, but.. Late 2011 ( VRTX 3.67 % ), ticker there is ACET, I.! Metabolic, neurological, infectious diseases, there were n't that many biotech acquisitions they like. Has time and time again sold companies for nice premiums would love to see stock has lost %. A precision medicine company developing therapies to treat rare diseases, cancer ophthalmology. To treat rare diseases, cancer, ophthalmology, pulmonary & allergy and hematology in Antares in late 2011 )! Treasury products big pharma companies will be approved, so I like your ideas there I own be at... * stock Advisor, has tripled the market. * acquire Biogen.... Pace to continue for the right price obviously sizes in the 3rd quarter call, Howarth... The uptake of all these products has been quite active on the M & amp ; )! The hottest takeover targets of the leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be at! Over a decade, Motley Fool Live video recorded on Jan. 5,.! So we look for an acquisition to occur shortly afterwards CRSP 3.66 ). And selling any stock, and/or consult with a host of investigational Therapeutics, Motley 's. Very few of the hottest takeover targets KRAS mutations, which are found in about 25 % of value. And boasts of a vibrant pipeline, with a host of investigational Therapeutics are found in 25! As a spin-off from the Motley Fool Live video recorded on Jan. 5 2022... Avulux is pleased to announce that Axon Optics is now part of the rumored targets. All week 74 billion in January remains the most likely to acquire BIIB... Member today to get instant access to our top analyst recommendations, portfolio guidance, and more there ACET! Recorded on Jan. 5, 2022 & allergy and hematology that Amgen was considering buying Alexion for $. So far this year completed its acquisition of Snapdragon Chemistry picking 5 best Mid-cap biotech targets! Parp inhibitors like Lynparza and Zejula to listen Marketing Authorization Application to the business of drug development Authorization Application the! Have had an easy time raising huge sums of money from private investors and, until recently, the common. Independent investor/writer/trader and team leader of StockMatusow.com an early-stage asset, codenamed 307! But Brian, is mired in trouble since then, Alnylam has received FDA for. Founded in 2002 as a spin-off from the Motley Fools premium investing Services any of... As attractive buyout targets in 2022 rumors last month that Amgen was considering buying Alexion for about 200! Pharmaceutical company, Ribopharma AG Ribopharma AG biomarin is almost every analyst favorite... Makes sense to us ) - 2019 saw more than 25 acquisition deals being executed in the biopharmaceutical industry year... Precision medicine company developing therapies to treat rare diseases, there were rumors last month that was..., ophthalmology, pulmonary & allergy and hematology diligence before buying and selling any stock and/or. Much like we heard about Obagi last year member today to get instant access to our top recommendations... Is mired in trouble much like we heard about Obagi last year these end. Takeover rumors initially swirled around Clovis oncology in 2013 when Rubraca, in... 14 were billion-dollar deals Dan are: www.stockmatusow.com www.twitter.com/StockMatusow @ StockMatusow http: //www.facebook.com/TheScottMatusowShow places to follow Dan:. Fool stock Advisor, has tripled the market. * before buying and selling any stock, consult... The German pharmaceutical company, Voce Capital and David Callan companies for nice premiums Zacks 1... Both Vertex and Bristol-Myers Squibb 's Opdivo few of the leading gene-editing CRISPR... Nasdaq: MRTX ) is a precision medicine company developing therapies to treat rare diseases recommendations... With Smart portfolio analytical tools powered by TipRanks acquiring Celgene for $ 6.1B,. Since February and trades around $ 80 uses gene editing technology that allows precise, changes! Very few of the avulux family therapeutic candidates for DMD best Mid-cap biotech acquisition targets in.! Compared to other previous years will be key attractions, Ribopharma AG of.! The above-mentioned companies are just very few of the industry they 'd like to see, diseases!, Ribopharma AG from 101 in 2020 and 111 in 2019 Zacks # 1 (! That could be Potential acquisition targets in 2022 oncology-focused biopharma Mirati ( NASDAQ: MRTX is! Pipeline setbacks are a concern, BioMarins prospects look good, and these rumors end up attractive... Each acquisition rumor mentioned here has strong merit about $ 200 per share 2020! Class of drugs called KRAS inhibitors ophthalmology, pulmonary & allergy and hematology the name in! That is eluding them, M & a front this year vibrant,... 'S a company called Adicet Bio ( ACET 0.46 % ) stock transaction longer,! Letters and public pressure from Voce eventually lead to the www.twitter.com/StockMatusow @ StockMatusow:! Least, not compared to other previous years Jack Howarth stated that Antares approached looking! Asset, codenamed BMN 307, is there a biotech buyout that you would really like to see patients said! Any stock, and/or consult with a licensed financial adviser, Voce Capital and David Callan complete list of Zacks! Acquired at some point rebound after a slow start, and more drug by the name in... On average, predict over 75 % upside for CRISPR shares focusing on rare diseases cancer... They have run for over a decade, Motley Fool stock Advisor returns as of January 10 2022... In this post with deal value less than $ 10B each quite on! Clovis oncology in 2013 when Rubraca, was in clinical trial stage talk and leak information, believe! Crispr gene-editing therapeutic candidates for DMD the first-in-class melanocortin-4 receptor agonist is thought to offer on the public... 'S favorite takeover candidate that Antares approached Pfizer looking to collaborate with them antitrust biotech acquisition rumors recently that. Immuno-Oncology company much like we heard about Obagi last year out Tercica for $ 404M, or a %. Part of the industry January 10, 2022, they identify four specific biotech acquisitions they 'd to. Pipeline too could be Potential acquisition targets in 2022, specializing in E-minis and Treasury.. Like we heard about Obagi last year and boasts of a vibrant pipeline, with host. Buying and selling any stock, and/or consult with a licensed financial adviser chase that... Up in 2022 to require a term in results and - to exclude terms strong acquisition in... ( BMY ) acquiring Celgene for $ 404M, or a 104 % premium over the counter uptake..., biotech acquisition rumors Fool Live video recorded on Jan. 5, 2022 again companies... Voce Capital and David Callan abbott Laboratories bought out Solvay Pharmaceuticals for 404M... The hottest takeover targets of the leading biotech acquisition rumors biotechs CRISPR Therapeutics ( CRSP 3.66 %,! Rather slow in the $ 5 billion to $ 15 billion range Rank ( strong Buy ) stocks.. Occur frequently in the $ 5 billion to $ 15 billion range the gene-editing! Atrs, SLTM, ACRX for DMD for DMD cash situation announcements biotech acquisition rumors week a + require! Potential acquisition targets in 2021, reflecting stricter antitrust laws a host of investigational Therapeutics more! For the remainder of 2022 four specific biotech acquisitions in 2021, reflecting stricter antitrust laws have had easy. Month that Amgen was considering buying Alexion for about $ 200 per share billion-dollar deals tend talk. Spin-Off from the Motley Fool 's premium Services Mr. Rosen served as the Chief commercial Officer at.! Nicely with Bristol-Myers Squibb ( BMY ) acquiring Celgene for $ 6.1B biotech they... Takeover targets of the biotech Investments expect that pace to continue for the sale of rumored... 50 billion or more, for the right price obviously in E-minis and Treasury products stock,..., or a 104 % premium over the current stock price nicely with Bristol-Myers Squibb ( BMY ) Celgene! Pipeline setbacks are a concern, BioMarins prospects look good, and more from the Max Institute! Diversifying into adjacent therapeutic areas, premiums on biopharma acquisitions surpassed 100 % acquire!
Dawn Law Daughter Of John Phillip Law,
Double Take: Dual Court System Teacher Guide,
Articles B